This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?
by Zacks Equity Research
Growth in Jakafi sales are likely to help Incyte (INCY) to beat on earnings in Q4.
Solid Q4 Earnings Drive Pharma ETF Outlook
by Sweta Killa
Although pharma ETFs saw terrible trading over the past one month in the latest global market rout, the string of earnings beat bolstered confidence in the space.
Array's Melanoma Combo Shows Positive Overall Survival Data
by Zacks Equity Research
Array's (ARRY) shares gain on impressive overall survival data from a phase III trial of combined binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma.
Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study
by Zacks Equity Research
Bristol-Myers' (BMY) blockbuster drug, Opdivo, in combination with Yervoy, proves its worth again by demonstrating superiority in a lung cancer study.
ADP, Q4, SOTU Boost Market
by Zacks Equity Research
ADP, Q4, SOTU Boost Market
Markets Rebound Bigly on ADP, Q4, SOTU
by Mark Vickery
After two days of market sell-off, suddenly everything's coming up roses again.
Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance
by Zacks Equity Research
Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.
Eli Lilly (LLY) Tops Q4 Earnings & Sales, Ups 2018 View
by Zacks Equity Research
Eli Lilly (LLY) beat estimates on both counts in its fourth quarter earnings results.
Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX
by Zacks Equity Research
Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.
Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call
by Arpita Dutt
With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.
Merck Reports Positive Phase III Liver Cancer Data on Keytruda
by Zacks Equity Research
Merck (MRK), announces first time results from the phase II study evaluating the use Keytruda in patients with advanced hepatocellular carcinoma (HCC), previously treated with sorafenib.
Merck Strong on Confirmatory Phase III Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda in combination with Eli Lilly's Alimta and carboplatin meet dual primary endpoints in a confirmatory phase III study for the first-line treatment of lung cancer.
Nektar Boasts Strong Pipeline, Competition Remains a Woe
by Zacks Equity Research
Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.
Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod
by Zacks Equity Research
Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.
Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?
by Zacks Equity Research
Merck's (MRK) Keytruda rapidly grows as its key top-line driver. The Keytruda development program shows significant advancement in 2017.
Big Pharma CEOs Speak About Impact of Tax Reform on M&A
by Zacks Equity Research
This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.
FDA Approvals Surge in 2017: Here's a Look at the Numbers
by Arpita Dutt
There was a significant surge in FDA approvals in 2017 with the regulatory body giving its nod to 46 novel drugs plus gene-based therapies like Novartis's (NVS) Kymriah. Here is a closer look at the numbers and what lies ahead.
Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs
by Zacks Equity Research
Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.
Alzheimer's takes Another Hit as Pfizer Ends Research in this Area
by Arpita Dutt
With pharma major, Pfizer (PFE), announcing its intention to drop plans to develop treatments for Alzheimer's and certain other disease areas, here is a look at what is going on in this corner of the market.
Merck's Keytruda Gets Approved for Bladder Cancer in Japan
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.
ImmunoGen (IMGN) Soars Above 200% This Year: Here's Why
by Zacks Equity Research
ImmunoGen's (IMGN) shares shoot up in the year on rapid pipeline progress, positive study data and strategic collaborations.
The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom
Biogen's Alzheimer's Drug Misses Goal in Interim Analysis
by Zacks Equity Research
Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.
AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study
by Zacks Equity Research
AbbVie's (ABBV) RA candidate, upadacitinib, achieves statistically significant improvement in patients in phase III monotherapy study comparing it to methotrexate.